Drug Profile
Foscarbidopa/foslevadopa - Abbvie
Alternative Names: ABBV 951; Foslevodopa/foscarbidopa; Levodopa/carbidopa prodrug; PRODUODOPA; VYALEV; VyalevLatest Information Update: 12 Feb 2024
Price :
$50
*
At a glance
- Originator AbbVie
- Class Antiparkinsonians; Aromatic amino acids; Carboxylic acids; Catecholamines; Hydrazines; Phosphates; Small molecules
- Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Parkinson's disease
Most Recent Events
- 08 Feb 2024 Launched for Parkinson's disease (Treatment-resistant) in Canada (SC)
- 09 Jan 2024 Launched for Parkinson's disease in Sweden, Hungary (SC)
- 22 Apr 2023 Pharmacokinetics data from a phase I trial in healthy volunteers presented at the 75th Annual Meeting of the American Academy of Neurology (AAN-2023)